Digestive Disease Week (DDW) 2022

The investigational microbiota-based live biotherapeutic RBX2660 is safe and averts repeat episodes of Clostridioides difficile infection (CDI) across patient populations with comorbid conditions, as shown in a study presented at Digestive Disease Week (DDW) 2022.

Treatment with tenapanor improves symptoms in patients with irritable bowel syndrome with constipation (IBS-C) as early as week 1 of treatment, according to two phase III studies presented at DDW 2022.

Antibiotic use appears to be harmful for older adults, with a recent study showing that regardless of class, the drugs raise the risk of developing inflammatory bowel disease (IBD).

Individuals with nonalcoholic fatty liver disease (NAFLD) – despite having a lean body or healthy BMI – are at an elevated risk for peripheral vascular disease, stroke, and cardiovascular disease (CVD), a finding that surprises gastroenterologists and researchers at DDW 2022.

Use of statins results in reduced all-cause mortality in nearly 30,000 veterans with colorectal cancer (CRC), results of a study have shown.

Counselling for alcohol dependence and abuse can help reduce the 30-day readmission rates for alcoholic hepatitis (AH), according to a study presented at the recently concluded 2022 Digestive Disease Week (DDW 2022).

Patients who take multivitamin supplements at a moderate dose following their diagnosis of nonmetastatic colorectal cancer (CRC) appear to have a lower mortality, reports a recent study.

A defecation posture modification device (DPMD), also known as a potty stool, is both safe and beneficial for children with functional constipation (FC), helping them wean off pharmacotherapy and improving their bowel function, according to a study presented at the recently concluded 2022 Digestive Disease Week (DDW 2022).